Literature DB >> 30824144

Design and implementation of a radiation dose tracking and reporting system for mammography and digital breast tomosynthesis.

Bruno Barufaldi1, Homero Schiabel2, Andrew D A Maidment3.   

Abstract

A tracking system has been implemented to monitor radiation dose for digital mammography (DM) and digital breast tomosynthesis (DBT). This system communicates with a PACS through DICOM messages that allow the image metadata to be stored in a relational database. The tracking system accepts X-ray breast images, maps the image metadata into a SQL database, and allows a client-side application to report the data using a business intelligence framework. The database contains the DICOM information of 54,244 studies (235,225 images) acquired from four Selenia Dimensions systems. The average time to receive the images, and then extract and write the metadata into the database is 2.28 s for a DM and 3.84 s for a DBT image. Using the stored metadata, physics reports are generated based on chosen criteria (i.e., system model, mammography unit, breast data, acquisition techniques, physician, etc.). Our results show that the mean average glandular dose (AGD) varies significantly with compressed breast thickness and age. We observed an overall dose increase of 25.6% between DM and DBT (1.76 vs 2.21 mGy).
Copyright © 2019 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DICOM; Digital breast tomosynthesis; Digital mammography; PACs

Mesh:

Year:  2019        PMID: 30824144      PMCID: PMC6404780          DOI: 10.1016/j.ejmp.2019.02.011

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  1 in total

1.  Characterization of the imaging settings in screening mammography using a tracking and reporting system: A multi-center and multi-vendor analysis.

Authors:  Bruno Barufaldi; Samantha P Zuckerman; Regina B Medeiros; Andrew D Maidment; Homero Schiabel
Journal:  Phys Med       Date:  2020-03-03       Impact factor: 2.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.